Core Viewpoint - RenovoRx, Inc. has successfully closed an oversubscribed private placement, raising approximately $10 million to support its business plan and clinical milestones, particularly for its FDA-cleared drug-delivery device, RenovoCath [1][3][6] Financing Details - The private placement was led by both new and existing institutional investors, including Transcend Partners, LLC and AIGH Capital Management LLC, with participation from RenovoRx's senior management and Board of Directors [2] - A total of 10,638,790 shares of common stock were issued at a price of $0.938 per share, along with revenue milestone warrants for an additional 5,319,392 shares [4] - The exercise price for the revenue milestone warrants is set at $1.751, representing a 100% premium to the offering price [5] Business Strategy and Milestones - The proceeds from the financing will be utilized to accelerate the market adoption of RenovoCath and advance clinical development, with a focus on achieving full enrollment in the pivotal Phase III trial by mid-2026 [3][7] - The company anticipates significant growth in commercial revenues, which will help reduce cash burn and support the goal of cash-flow breakeven operations [3] Leadership and Team - Mark Voll has been appointed as Chief Financial Officer, bringing a strong track record of scaling public companies [3] - The company has established a core, nimble, and capital-efficient commercial team for RenovoCath [3] Clinical Development - RenovoRx is nearing completion of enrollment in its pivotal Phase III TIGeR-PaC clinical trial, with results expected in 2027 [3][7] - The trial involves 16 additional commercial centers that are already trained on RenovoCath procedures and have begun purchasing devices [3] Product Overview - RenovoCath is designed for targeted delivery of fluids to specific sites in the peripheral vascular system and is indicated for temporary vessel occlusion [10][11] - The company is also evaluating a novel drug-device combination product candidate, intra-arterial gemcitabine delivered via RenovoCath, in the ongoing Phase III trial [13][14]

Core Insights - New to The Street is a prominent financial media brand that broadcasts weekly on Bloomberg Television and Fox Business, reaching millions of households across the U.S., Latin America, and MENA regions [6] Group 1: Featured Companies - FreeCast (NASDAQ:CAST) is transforming digital media aggregation and streaming access for consumers worldwide [3] - KLED.ai is advancing AI-driven enterprise and data intelligence solutions [3] - Lantern Pharma (NASDAQ:LTRN) is a leader in AI-powered oncology drug development [3] - BlackBarn Restaurant is a premier culinary destination in New York City known for its farm-to-table excellence [3] - Virtuix (NASDAQ:VRTX) specializes in immersive virtual reality technology [4] - NRx Pharmaceuticals (NASDAQ:NRXP) focuses on advanced therapeutics for critical conditions [4] - PetVivo Holdings is involved in veterinary regenerative medicine [4] - DataVault AI (NASDAQ:DVLT) provides data monetization and tokenization infrastructure [4] - Roadzen (NASDAQ:RDZN) offers an AI-powered insurance and mobility platform [4] - Stardust Power (NASDAQ:SDST) is engaged in lithium and energy infrastructure solutions [4] - CISO Global (NASDAQ:CISO) is an enterprise cybersecurity leader [4] - The Sustainable Green Team (OTC:SGTM) focuses on climate and sustainable infrastructure solutions [4] Group 2: Media Reach and Impact - New to The Street has a combined platform reach exceeding 5.1 million subscribers, including 4.44 million on its YouTube channel and over 700,000 on the NewsOut Digital Network [4][5] - The platform utilizes various distribution channels, including LinkedIn, X, Instagram, and Facebook, along with iconic billboard placements in Times Square and NYC's Financial District [4] - New to The Street continues to outperform traditional financial media platforms in terms of reach, engagement, and measurable impact, establishing itself as a dominant force in next-generation financial media [5]

Core Viewpoint - RenovoRx, Inc. is set to announce its fourth quarter and full year 2025 financial results and business highlights on March 30, 2026, showcasing its progress in oncology therapies and the commercialization of its FDA-cleared drug-delivery device, RenovoCath [1][4]. Group 1: Financial Results and Conference Call - The conference call will take place on March 30, 2026, at 4:30 p.m. ET, where management will discuss financial results and business highlights [1][4]. - A recording of the call will be available on the Investor Relations website, with a dial-in replay accessible until April 13, 2026 [4]. Group 2: Clinical Pipeline and Product Development - Management will provide updates on the clinical pipeline, particularly the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is on track for enrollment completion in the first half of 2026, with final data expected in 2027 [3]. - The company is focusing on generating new data through post-marketing registry studies and supporting investigator-initiated trials (IIT) in pancreatic cancer, which are designed to be cost-neutral and provide meaningful data for the TAMP™ therapy platform [3]. Group 3: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath, having received its first commercial purchase orders in December 2024, generating approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [6]. - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [6]. Group 4: Product Candidates and Regulatory Status - RenovoRx is evaluating its intra-arterial gemcitabine product candidate delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial, which is regulated under a U.S. investigational new drug application [7]. - The IAG combination product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Insights - Guardant Health will present 28 abstracts at the AACR Annual Meeting 2026, focusing on advancements in tumor typing, therapy selection, and the utility of multiomic tissue and liquid biopsy testing [1][2] Group 1: Presentation Highlights - Key data will showcase the effectiveness of blood- and tissue-based tests in addressing critical gaps in cancer care, including identifying unknown primary cancers and expanding treatment options [2] - Guardant360 Tissue has shown strong performance in determining tissue of origin in challenging diagnostic settings, with a 92% accuracy rate across over 6,000 samples and 24 tumor types [4] - Guardant Reveal demonstrates expanded utility in identifying new primary cancers during minimal residual disease (MRD) monitoring, highlighting its potential for non-invasive detection [4] Group 2: Specific Studies and Findings - Research indicates that a tissue-based genomic instability score can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers, identifying patients who may benefit from PARP inhibitors [4] - Guardant360 Liquid has actionable findings for 85% of metastatic breast cancer patients and 89% of advanced colorectal cancer patients, showcasing its clinical actionability [4] - The presentations will include a focus on the clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers [5] Group 3: Presentation Schedule - Notable presentations include: - A methylation-based molecular tumor typing classifier for cancers of unknown primary on April 19, 2026 [5] - Tissue-based homologous recombination deficiency status prediction in breast, ovarian, and pancreatic cancers on April 20, 2026 [5] - Exploring clinical actionability of expanded liquid biopsy on April 21, 2026 [5] Group 4: Company Overview - Guardant Health is a leading precision oncology company focused on transforming patient care through advanced blood and tissue tests, real-world data, and AI analytics [10] - The company aims to improve outcomes across all stages of cancer care, from early screening to treatment selection for advanced cancer [10]

Core Insights - Messino Cancer Centers has opened its sixth location in Asheville, North Carolina, enhancing oncology care for local patients [1][3] - The new clinic is designed to provide high-quality, patient-centered cancer care, featuring private exam rooms, an on-site laboratory, and an infusion suite [2][4] Company Overview - Messino Cancer Centers specializes in treating adult patients with various types of cancer and blood disorders, emphasizing personalized care in community settings [5][7] - The organization has a 30-year history of delivering high-quality cancer treatment based on research and focused on the whole person [5][7] Partnership and Network - Messino Cancer Centers is a partner of the American Oncology Network (AON), which is one of the fastest-growing community-based oncology networks in the U.S. [3][8] - AON supports its network of over 350 providers across 21 states, promoting innovative healthcare solutions and value-based care to improve patient outcomes [8]

Core Insights - Aditxt has acquired Ignite Proteomics to enhance cancer care by optimizing therapy selection for patients with metastatic cancer and limited treatment options [1][2] - Ignite's functional proteomics platform can identify therapy responses that standard genomic testing may miss, addressing a significant challenge in precision oncology [1] Group 1: Acquisition Details - Aditxt acquired Ignite Proteomics for an aggregate value of $36 million, represented by 36,000 shares of Series A-2 Convertible Preferred Stock [2] - Ignite will function as a subsidiary within Aditxt's oncology initiatives, focusing on therapy selection and longitudinal monitoring [2] Group 2: Market Opportunity - The global cancer profiling market is estimated at approximately $14 billion, with Ignite identifying a $3 billion serviceable opportunity among patients eligible for antibody drug conjugate therapies [1] - The demand for tools that determine whether a patient's tumor expresses functional protein targets is increasing due to the expansion of targeted cancer therapies [1] Group 3: Functional Proteomics Platform - Ignite's Reverse Phase Protein Array (RPPA) platform measures protein expression and activity, providing insights that complement genomic testing [1] - The platform has shown potential in predicting therapy responses, outperforming traditional assays in clinical trials [1] Group 4: Collaborations and Validation - Ignite is collaborating with leading cancer institutions, including Dana-Farber Cancer Institute and Vanderbilt University Medical Center, to validate its platform [1] - A partnership with Inova Health aims to apply the RPPA platform to guide treatment decisions for late-stage gastrointestinal cancer patients [1]

Core Insights - A recent survey by Guardant Health and Harris Poll reveals that 92% of Americans aged 45 and over believe that blood-based colorectal cancer screening should be accessible and covered without co-pay, similar to Medicare [1] - The Shield test by Guardant Health, a non-invasive blood-based screening for colorectal cancer, has shown a 93% adherence rate, significantly improving screening rates compared to traditional methods [1] - The survey highlights barriers to colorectal cancer screening, with 54% of respondents finding stool-based tests unappealing and 71% expressing anxiety about colonoscopies [1] Company Overview - Guardant Health is a leading precision oncology company focused on enhancing patient care and accelerating cancer therapies through advanced blood and tissue tests [1] - The Shield test is the first and only FDA-approved blood test for primary colorectal cancer screening, intended for individuals aged 45 and older at average risk [1] - Guardant Health's Shield test is covered by Medicare, Veterans Affairs Community Care Network, and TRICARE, making it widely accessible across the U.S. [1] Industry Context - Colorectal cancer is the second leading cause of cancer-related deaths in the U.S., with a 91% five-year survival rate if detected early [1] - The U.S. Preventive Services Task Force updated national CRC screening guidelines in 2021, lowering the recommended screening age from 50 to 45, but has yet to include the new Shield test in its recommendations [1] - The National Comprehensive Cancer Network has recently included the Shield blood test in its updated CRC screening guidelines, indicating a shift towards improved patient access [1]

Core Insights - Tempus AI, Inc. has published a study in JCO Precision Oncology demonstrating the importance of advanced genomic profiling features in identifying clinically actionable findings for cancer patients [1] - The study indicates that 12% of patients had potentially actionable findings linked to approved therapies that were only identified through advanced features like tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex testing [1] Group 1: Study Findings - Advanced genomic profiling (CGP) expands treatment options for cancer patients in community oncology settings [1] - Current guidelines from organizations like ASCO and NCCN lack specificity on essential features required in genomic panels, highlighting the need for comprehensive testing [1] - The study emphasizes that CGP's value extends beyond panel size, showcasing the utility of advanced testing features in capturing clinically relevant findings [1] Group 2: Company Overview - Tempus is a technology company focused on advancing precision medicine through AI applications in healthcare [1] - The company possesses one of the largest libraries of multimodal data, providing AI-enabled precision medicine solutions to physicians [1] - Tempus aims to enhance personalized patient care and facilitate the discovery and development of optimal therapeutics [1]

Core Insights - The Oncology Institute, Inc. (TOI) will release its fourth quarter and full year 2025 financial results on March 12, 2026, followed by a conference call at 5:00 p.m. Eastern Time [1] Financial Results Announcement - The financial results will be announced on March 12, 2026 [1] - A conference call will take place on the same day at 5:00 p.m. Eastern Time [1] Conference Call Access - The conference call can be accessed by phone at 1-877-407-0789 for domestic callers and 1-201-689-8562 for international callers [2] - A replay of the call will be available two hours after it concludes, accessible at 1-844-512-2921 for domestic and 1-412-317-6671 for international callers, with a passcode of 13758646 [2] - The replay will be available until March 19, 2026 [2] Webcast Information - Interested parties can listen to a simultaneous webcast of the conference call via the Investor Relations section of TOI's website [3] Company Overview - The Oncology Institute, founded in 2007, specializes in value-based cancer care in community settings [4] - TOI serves approximately 1.9 million patients and offers advanced cancer care services, including clinical trials and transfusions [4] - The company employs over 180 clinicians and operates more than 100 clinics across five states [4]

Core Insights - Terns Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing high-impact medicines, with its lead program TERN-701 being a selective BCR-ABL inhibitor aimed at improving treatment for chronic myeloid leukemia (CML) [3] Upcoming Investor Conferences - Terns Pharmaceuticals will participate in several investor conferences in March 2026, including: - TD Cowen's 46th Annual Health Care Conference on March 2, 2026, at 3:50 p.m. ET in Boston, MA [2] - Leerink Global Healthcare Conference on March 9, 2026, at 1:40 p.m. ET in Miami, FL [2] - Barclays 28th Annual Global Healthcare Conference on March 10, 2026, in Miami, FL [2] - The Citizens Life Sciences Conference on March 11, 2026, at 9:00 a.m. ET in Miami, FL [2] - Live webcasts of the fireside chats will be available on Terns' investor relations page, with replays archived for at least 30 days [2]